Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.

Biomark Res · 2023 · PMC9990338 · PMID 36879284

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP = 0.11not close (p > 0.1)

showed a trendno p-value reported

More prominently, patients with high Mφ density (CD68 Hi ) showed a trend towards a longer median OS compared with patients with low Mφ density (CD68 Lo ), although this did not reach statistical significance (15.0 months vs. 10.4 months, P = 0.11; Fig. 1 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.